ReviewSTAR protocols2026
Overcoming the challenges of genome-editing essential genes.
Review in STAR protocols, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This primer manuscript summarizes gene-editing strategies for limiting gene-editing activity with the aim of avoiding biallelic disruption. Mono-allelic editing of cells and embryos is advantageous when modeling dominant genetic disorders or when addressing essential or developmentally important genes, loss of function of which leads to severe phenotypes. Gene-editing reagents, such as the CRISPR-Cas9 system, are very efficient and frequently result in bi-allelic mutation of the selected target site. The article introduces different strategies for restricting editing to a single allele, exploring modifications to both the delivery of the gene-editing reagents and to the enzymes commonly used for gene editing themselves, along with design considerations for both the target sites and the repair template when trying to achieve knockin mutations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.